Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve clinical and mortality outcomes in individuals with type 2 diabetes, chronic kidney disease, and heart failure [1, 2]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.